Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer

R. Farkas, E. Pozsgai, S. Bellyei, L. Cseke, A. Szigeti, A. Vereczkei, S. Marton, L. Mangel, O. Horvath, Andras Papp

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Possible predictive markers of response to neoadjuvant radiochemotherapy (NRCT) of esophageal cancer have been identified. Patients and Methods: Patient biopsies were obtained from both tumor and normal tissue before the NRCT of locally advanced esophageal squamous cell carcinoma. Protein solutions were separated and immunoblot analysis was performed with heat shock protein (Hsp) 16.2, heme-binding protein 2 (SOUL), BCL2-associated X protein (Bax), B-cell-associated leukemia protein 2 (Bcl-2) and heat shock protein 90 (Hsp90) antibodies. Following NRCT, the patients were restaged according to the Response Evaluation Criteria In Solid Tumors (RECIST). Following resections the pathological down-staging was evaluated. Results: Clinical restaging revealed a response rate of 65%. Pathological examination revealed down-staging in 30% and 25% of the cases for the T and N categories respectively. Compared to the normal esophageal mucosa, a decreased expression of Hsp16.2, Hsp90 and SOUL proteins and an increased Bax/Bcl-2 ratio was found in the responding tumors. Conclusion: Hsp16,2, Hsp90 and SOUL expression and Bax/ Bcl-2 ratio correlates to the efficacy of NRCT and predict outcome in patients with locally advanced squamous-cell esophageal cancer.

Original languageEnglish
Pages (from-to)1769-1775
Number of pages7
JournalAnticancer Research
Volume31
Issue number5
Publication statusPublished - May 2011

Fingerprint

Squamous Cell Neoplasms
Neoadjuvant Therapy
Chemoradiotherapy
B-Cell Leukemia
Esophageal Neoplasms
HSP90 Heat-Shock Proteins
Proto-Oncogene Proteins c-bcl-2
Neoplasms
Proteins
Heat-Shock Proteins
Biopsy
Antibodies
IgA receptor

Keywords

  • Neoadjuvant therapy
  • Response prediction
  • Squamous-cell esophageal cancer
  • Tumor-associated proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer. / Farkas, R.; Pozsgai, E.; Bellyei, S.; Cseke, L.; Szigeti, A.; Vereczkei, A.; Marton, S.; Mangel, L.; Horvath, O.; Papp, Andras.

In: Anticancer Research, Vol. 31, No. 5, 05.2011, p. 1769-1775.

Research output: Contribution to journalArticle

Farkas, R. ; Pozsgai, E. ; Bellyei, S. ; Cseke, L. ; Szigeti, A. ; Vereczkei, A. ; Marton, S. ; Mangel, L. ; Horvath, O. ; Papp, Andras. / Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer. In: Anticancer Research. 2011 ; Vol. 31, No. 5. pp. 1769-1775.
@article{f7625797e6a342098b26723809a644ee,
title = "Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer",
abstract = "Background: Possible predictive markers of response to neoadjuvant radiochemotherapy (NRCT) of esophageal cancer have been identified. Patients and Methods: Patient biopsies were obtained from both tumor and normal tissue before the NRCT of locally advanced esophageal squamous cell carcinoma. Protein solutions were separated and immunoblot analysis was performed with heat shock protein (Hsp) 16.2, heme-binding protein 2 (SOUL), BCL2-associated X protein (Bax), B-cell-associated leukemia protein 2 (Bcl-2) and heat shock protein 90 (Hsp90) antibodies. Following NRCT, the patients were restaged according to the Response Evaluation Criteria In Solid Tumors (RECIST). Following resections the pathological down-staging was evaluated. Results: Clinical restaging revealed a response rate of 65{\%}. Pathological examination revealed down-staging in 30{\%} and 25{\%} of the cases for the T and N categories respectively. Compared to the normal esophageal mucosa, a decreased expression of Hsp16.2, Hsp90 and SOUL proteins and an increased Bax/Bcl-2 ratio was found in the responding tumors. Conclusion: Hsp16,2, Hsp90 and SOUL expression and Bax/ Bcl-2 ratio correlates to the efficacy of NRCT and predict outcome in patients with locally advanced squamous-cell esophageal cancer.",
keywords = "Neoadjuvant therapy, Response prediction, Squamous-cell esophageal cancer, Tumor-associated proteins",
author = "R. Farkas and E. Pozsgai and S. Bellyei and L. Cseke and A. Szigeti and A. Vereczkei and S. Marton and L. Mangel and O. Horvath and Andras Papp",
year = "2011",
month = "5",
language = "English",
volume = "31",
pages = "1769--1775",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer

AU - Farkas, R.

AU - Pozsgai, E.

AU - Bellyei, S.

AU - Cseke, L.

AU - Szigeti, A.

AU - Vereczkei, A.

AU - Marton, S.

AU - Mangel, L.

AU - Horvath, O.

AU - Papp, Andras

PY - 2011/5

Y1 - 2011/5

N2 - Background: Possible predictive markers of response to neoadjuvant radiochemotherapy (NRCT) of esophageal cancer have been identified. Patients and Methods: Patient biopsies were obtained from both tumor and normal tissue before the NRCT of locally advanced esophageal squamous cell carcinoma. Protein solutions were separated and immunoblot analysis was performed with heat shock protein (Hsp) 16.2, heme-binding protein 2 (SOUL), BCL2-associated X protein (Bax), B-cell-associated leukemia protein 2 (Bcl-2) and heat shock protein 90 (Hsp90) antibodies. Following NRCT, the patients were restaged according to the Response Evaluation Criteria In Solid Tumors (RECIST). Following resections the pathological down-staging was evaluated. Results: Clinical restaging revealed a response rate of 65%. Pathological examination revealed down-staging in 30% and 25% of the cases for the T and N categories respectively. Compared to the normal esophageal mucosa, a decreased expression of Hsp16.2, Hsp90 and SOUL proteins and an increased Bax/Bcl-2 ratio was found in the responding tumors. Conclusion: Hsp16,2, Hsp90 and SOUL expression and Bax/ Bcl-2 ratio correlates to the efficacy of NRCT and predict outcome in patients with locally advanced squamous-cell esophageal cancer.

AB - Background: Possible predictive markers of response to neoadjuvant radiochemotherapy (NRCT) of esophageal cancer have been identified. Patients and Methods: Patient biopsies were obtained from both tumor and normal tissue before the NRCT of locally advanced esophageal squamous cell carcinoma. Protein solutions were separated and immunoblot analysis was performed with heat shock protein (Hsp) 16.2, heme-binding protein 2 (SOUL), BCL2-associated X protein (Bax), B-cell-associated leukemia protein 2 (Bcl-2) and heat shock protein 90 (Hsp90) antibodies. Following NRCT, the patients were restaged according to the Response Evaluation Criteria In Solid Tumors (RECIST). Following resections the pathological down-staging was evaluated. Results: Clinical restaging revealed a response rate of 65%. Pathological examination revealed down-staging in 30% and 25% of the cases for the T and N categories respectively. Compared to the normal esophageal mucosa, a decreased expression of Hsp16.2, Hsp90 and SOUL proteins and an increased Bax/Bcl-2 ratio was found in the responding tumors. Conclusion: Hsp16,2, Hsp90 and SOUL expression and Bax/ Bcl-2 ratio correlates to the efficacy of NRCT and predict outcome in patients with locally advanced squamous-cell esophageal cancer.

KW - Neoadjuvant therapy

KW - Response prediction

KW - Squamous-cell esophageal cancer

KW - Tumor-associated proteins

UR - http://www.scopus.com/inward/record.url?scp=79958119374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958119374&partnerID=8YFLogxK

M3 - Article

C2 - 21617238

AN - SCOPUS:79958119374

VL - 31

SP - 1769

EP - 1775

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -